search
Back to results

Comparing Radical Surgery and Radical Radiotherapy as First Definitive Treatment for Primary MCC (Rational-MCC)

Primary Purpose

Merkel Cell Carcinoma

Status
Active
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Radiotherapy
Surgery
Sponsored by
University of Birmingham
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Merkel Cell Carcinoma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

General Inclusion Criteria for All Patients:

  1. Patients newly diagnosed with histologically-proven MCC (either primary and/or regional nodal disease)
  2. Completion of clinical and radiological staging investigations, including CT imaging (or other modality) of regional nodal basin(s) and major viscera (and SLNB if clinically appropriate) to identify regional and distant metastases
  3. No confirmed distant metastases beyond the regional nodal basin (i.e. not stage IV disease)
  4. Suitable for radical treatment to achieve disease control
  5. Able to give valid informed consent
  6. Consent for collection of data and tissue samples and follow up
  7. Life expectancy six months or greater in relation to general fitness and co-morbidities

Additional Inclusion Criteria for Rational Compare:

  1. Patients newly diagnosed with histologically-proven primary MCC
  2. In the opinion of the SSMDT, the primary MCC can be encompassed both within a wide surgical margin and within a radiotherapy field, and the SSMDT is in equipoise regarding WLE or radiotherapy as first treatment
  3. A minimum margin of 1 cm surrounding the MCC achievable by either radiotherapy or surgery
  4. Consent for randomisation into Rational Compare

Exclusion Criteria:

  1. The primary MCC has already been treated radically with WLE (surgical margins >10 mm) or radiotherapy
  2. Intended use of regional or systemic chemotherapy for MCC (including molecularly targeted agents and immunotherapy)

Sites / Locations

  • University Hospital Birmingham NHS Foundation Trust
  • North Bristol NHS Trust
  • Cambridge University Hospitals NHS Foundation Trust
  • NHS Tayside
  • Barts Health NHS Trust
  • Christie NHS Foundation Trust
  • Norfolk and Norwich University Hospitals NHS Foundation Trust
  • Nottingham University Hospitals NHS Trust
  • Oxford University Hospitals NHS Trust
  • St Helens and Knowsley Hospitals NHS Trust
  • Lancashire Teaching Hospitals NHS Foundation Trust
  • Sheffield Teaching Hospitals NHS Foundation Trust
  • University Hospital of North Midlands Trust
  • Royal Cornwall Hospitals NHS Trust

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Arm A: Prioritise Radiotherapy

Arm B: Prioritise Surgery

Arm Description

Radical radiotherapy to macroscopic tumour and/or to the tumour bed if already excised, plus a wide margin.

Wide Local Excision (WLE), aiming for complete excision of all MCC, plus a wide margin

Outcomes

Primary Outcome Measures

Time to loco-regional failure
The time to loco regional failure for all patients is the time from randomisation to loco-regional treatment failure

Secondary Outcome Measures

The proportion of patients alive and free of loco-regional disease
(irrespective of whether loco-regional failure has been previously demonstrated)
Time to 'local failure'-the time from randomisation to macroscopic persistence, progression or recurrence between the primary site and regional nodal basin(s)
(including in-field and in transit metastases)
Time to regional nodal failure
Time to regional nodal failure
Time to distant progression
Time to distant progression
Patient Progression free survival
Patient Progression free survival
Patient survival
Survival from randomisation
Quality of life assessed by questionnaires
Quality of life assessed by QLQC30/ EQ-5L-5D questionnaire completion

Full Information

First Posted
November 2, 2021
Last Updated
February 14, 2022
Sponsor
University of Birmingham
Collaborators
Efficacy and Mechanism Evaluation (EME) Programme
search

1. Study Identification

Unique Protocol Identification Number
NCT05253144
Brief Title
Comparing Radical Surgery and Radical Radiotherapy as First Definitive Treatment for Primary MCC
Acronym
Rational-MCC
Official Title
Rational-MCC: A Randomised Phase III Multi-centre Trial Comparing Radical Surgery and Radical Radiotherapy as First Definitive Treatment for Primary MCC
Study Type
Interventional

2. Study Status

Record Verification Date
February 2022
Overall Recruitment Status
Active, not recruiting
Study Start Date
March 19, 2016 (Actual)
Primary Completion Date
March 14, 2022 (Anticipated)
Study Completion Date
March 14, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Birmingham
Collaborators
Efficacy and Mechanism Evaluation (EME) Programme

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
A randomised phase III multi-centre trial comparing radical surgery and radical radiotherapy as first definitive treatment for primary MCC
Detailed Description
A randomised phase III multi-centre trial comparing radical surgery and radical radiotherapy as first definitive treatment for primary MCC with an observational study for patients ineligible for the randomised trial.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Merkel Cell Carcinoma

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Phase III
Masking
None (Open Label)
Allocation
Randomized
Enrollment
64 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Arm A: Prioritise Radiotherapy
Arm Type
Experimental
Arm Description
Radical radiotherapy to macroscopic tumour and/or to the tumour bed if already excised, plus a wide margin.
Arm Title
Arm B: Prioritise Surgery
Arm Type
Experimental
Arm Description
Wide Local Excision (WLE), aiming for complete excision of all MCC, plus a wide margin
Intervention Type
Radiation
Intervention Name(s)
Radiotherapy
Intervention Description
Radiotherapy
Intervention Type
Procedure
Intervention Name(s)
Surgery
Intervention Description
Surgery
Primary Outcome Measure Information:
Title
Time to loco-regional failure
Description
The time to loco regional failure for all patients is the time from randomisation to loco-regional treatment failure
Time Frame
Time from randomisation to 3 years
Secondary Outcome Measure Information:
Title
The proportion of patients alive and free of loco-regional disease
Description
(irrespective of whether loco-regional failure has been previously demonstrated)
Time Frame
Time from randomisation to 3 years
Title
Time to 'local failure'-the time from randomisation to macroscopic persistence, progression or recurrence between the primary site and regional nodal basin(s)
Description
(including in-field and in transit metastases)
Time Frame
Time from randomisation to 3 years
Title
Time to regional nodal failure
Description
Time to regional nodal failure
Time Frame
Time from randomisation to 3 years
Title
Time to distant progression
Description
Time to distant progression
Time Frame
Time from randomisation to 3 years
Title
Patient Progression free survival
Description
Patient Progression free survival
Time Frame
Time from randomisation to 3 years
Title
Patient survival
Description
Survival from randomisation
Time Frame
Time from randomisation to 3 years
Title
Quality of life assessed by questionnaires
Description
Quality of life assessed by QLQC30/ EQ-5L-5D questionnaire completion
Time Frame
Time from randomisation to 3 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: General Inclusion Criteria for All Patients: Patients newly diagnosed with histologically-proven MCC (either primary and/or regional nodal disease) Completion of clinical and radiological staging investigations, including CT imaging (or other modality) of regional nodal basin(s) and major viscera (and SLNB if clinically appropriate) to identify regional and distant metastases No confirmed distant metastases beyond the regional nodal basin (i.e. not stage IV disease) Suitable for radical treatment to achieve disease control Able to give valid informed consent Consent for collection of data and tissue samples and follow up Life expectancy six months or greater in relation to general fitness and co-morbidities Additional Inclusion Criteria for Rational Compare: Patients newly diagnosed with histologically-proven primary MCC In the opinion of the SSMDT, the primary MCC can be encompassed both within a wide surgical margin and within a radiotherapy field, and the SSMDT is in equipoise regarding WLE or radiotherapy as first treatment A minimum margin of 1 cm surrounding the MCC achievable by either radiotherapy or surgery Consent for randomisation into Rational Compare Exclusion Criteria: The primary MCC has already been treated radically with WLE (surgical margins >10 mm) or radiotherapy Intended use of regional or systemic chemotherapy for MCC (including molecularly targeted agents and immunotherapy)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Neil Steven
Organizational Affiliation
University of Birmingham
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital Birmingham NHS Foundation Trust
City
Birmingham
Country
United Kingdom
Facility Name
North Bristol NHS Trust
City
Bristol
Country
United Kingdom
Facility Name
Cambridge University Hospitals NHS Foundation Trust
City
Cambridge
Country
United Kingdom
Facility Name
NHS Tayside
City
Dundee
Country
United Kingdom
Facility Name
Barts Health NHS Trust
City
London
Country
United Kingdom
Facility Name
Christie NHS Foundation Trust
City
Manchester
Country
United Kingdom
Facility Name
Norfolk and Norwich University Hospitals NHS Foundation Trust
City
Norwich
Country
United Kingdom
Facility Name
Nottingham University Hospitals NHS Trust
City
Nottingham
Country
United Kingdom
Facility Name
Oxford University Hospitals NHS Trust
City
Oxford
Country
United Kingdom
Facility Name
St Helens and Knowsley Hospitals NHS Trust
City
Prescot
Country
United Kingdom
Facility Name
Lancashire Teaching Hospitals NHS Foundation Trust
City
Preston
Country
United Kingdom
Facility Name
Sheffield Teaching Hospitals NHS Foundation Trust
City
Sheffield
Country
United Kingdom
Facility Name
University Hospital of North Midlands Trust
City
Stoke-on-Trent
Country
United Kingdom
Facility Name
Royal Cornwall Hospitals NHS Trust
City
Truro
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Comparing Radical Surgery and Radical Radiotherapy as First Definitive Treatment for Primary MCC

We'll reach out to this number within 24 hrs